About this pathway
Background
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) approved for use in Japan.
The pharmacodynamics of lornoxicam has similarities with other NSAIDs such as that depicted for ibuprofen at Ibuprofen Pathway, Pharmacodynamics. Similar to ibuprofen, lornoxicam is non-selective and showed balanced inhibition of both PTGS1 and PTGS2 [Article:10450786].
The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. Dosage reduction for CYP2C9 poor metabolizers or *3 carriers is also discussed on the FDA label and in the FDA Table of Pharmacogenetic Associations.
Metabolism
Lornoxicam has a short half life of 3-5 hours. It is exclusively metabolized to 5'-hydroxylornoxicam by CYP2C9 [Articles:8857077, 15606435].
Reactions & interactions (2)
-
Biochemical Reaction
lornoxicam → 5'-hydroxylornoxicam
-
Catalysis
CYP2C9 → Biochemical Reaction
Edit history (2)
- 2021-06-09 Create
- 2025-06-27 Update fixed typo